Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Emerging hair loss treatments like PP405, a topical MPC inhibitor, show promise in activating stem cells for hair growth. The conversation seeks information on the development stages and accessibility of these treatments.

Pyrilutamide's 0.5% solution showed minimal improvement, while the 1% solution appears more promising but costly. The user is currently using finasteride and oral minoxidil and considering adding Pyrilutamide if effective and affordable.

Clascoterone 5% shows potential for hair thickening and darkening, especially when combined with treatments like finasteride. It may be a good alternative for those who experience side effects from other treatments.

People are discussing ordering pyrilutamide for hair loss treatment in the US. The treatment is from Kintor's subsidiary company and is available on Amazon.

The conversation discusses hair loss treatments, focusing on the anti-androgen component CB 03 01 and its systemic absorption and safety compared to finasteride. It highlights concerns about inhibiting DHT conversion and the safety of using clascoterone for hair loss.

The conversation discusses the potential availability and use of the pp405 molecule for hair loss treatment, with concerns about its legitimacy and safety on the grey market. Participants also mention using products from Umbrella Labs and discuss the concentration and production costs of pp405.

A 37-year-old is starting topical finasteride for hair loss, with lab results showing normal hormone levels. They plan to avoid further research initially and may share future lab results if significant side effects occur.

A user is considering finasteride for hair loss and is concerned about its effects on DHT levels and potential side effects, including those from creatine. The user seeks advice on finasteride's impact on hair and body hair, given their high DHT and testosterone levels.

The user has been using pyrilutamide 0.5% for over 7 weeks, alongside dutasteride, and noticed some hair improvement, particularly at the temples. They plan to continue and possibly try a 1% solution, with no shedding or side effects reported.

The conversation is about a user interested in participating in hair cloning clinical trials due to their fine hair and previous positive experience with clinical trials. They are seeking information on how to volunteer for such trials.

A user offers an extra bottle of Koshine 0.5% solution for hair loss. The discussion involves interest in trying Pyrilutamide for hair treatment.

Veradermics has a market cap over a billion dollars, comparable to Cosmo pharmaceutical. Users discuss using Kintor's Pirylutamide for hair loss.

The conversation discusses using Minoxidil, finasteride, RU58841, and pyrilutamide for hair loss treatment. The user is considering adding a topical treatment and has not experienced side effects from current treatments.

Women experienced severe reactions, including Topical Steroid Withdrawal (TSW), from using Winlevi (Clascoterone 1%) on their faces. Concerns were raised about the potential risks of higher concentrations, especially for hair loss treatment.

Minoxidil turned yellow/orange when mixed with bleach, suggesting its presence. However, this doesn't confirm the concentration of minoxidil.

The conversation provides scientific sources on hair loss treatments like finasteride, minoxidil, and others, aiming to help individuals make informed decisions about their treatment options. It also discusses phytochemicals as alternative treatments due to concerns about side effects from drug-based therapies.

Hair loss discussion includes Minoxidil, Finasteride, and RU58841 treatments. Pyrilutamide cleared for phase 3 clinical trial in China.

Pyrilutamide/KX-826 is being discussed for its effectiveness in hair regrowth, with some users reporting positive results, especially in early hair loss cases. Users have combined it with treatments like Minoxidil, and some experienced initial shedding before seeing regrowth.

PP405 is advancing to Phase 2b trials, showing promise from Phase 2a. It may be available in 3-6 years, with trials using a topical gel.

The conversation discusses the comparison of Pyrilutamide Phase II US trial results with 1 mg finasteride for hair loss treatment. It mentions that the total hair count increase in the US trial was not as good as the China trial.

PP405 is progressing to Phase 2b trials, with results expected in late 2025 or early 2026, and potential Phase 3 trials in 2026. Some users experienced side effects from finasteride and are hopeful for PP405 as an alternative treatment.

A user shared their one-year hair loss treatment progress using oral finasteride, topical finasteride/minoxidil, and microneedling, reporting no current side effects and significant hair improvement. They also use Head & Shoulders for dandruff control and recommend consistency in treatment.

The conversation discusses the anticipation of clascoterone scalp treatment results for hair loss, with concerns about its availability and high cost. Users express hope for positive outcomes and affordable access.

Reducing the dose of Pyrilutamide from 5mg to 2.5mg may still maintain hair loss results, but effectiveness can vary. Users discuss the cost and dosage implications, with some cautioning against reducing the dose due to its dose-dependent nature.

Clascoterone 5% solution showed a 539% improvement in hair count compared to placebo, but the actual increase in hair growth is minimal. Users express skepticism about the effectiveness of hair loss treatments.

The user has tried topical Minoxidil and oral Minoxidil for beard and scalp hair growth with minimal results, and has been on Finasteride for 7 months with stabilized scalp hair but no facial hair improvement. They are considering using a SULT1A1 enzyme booster to enhance results and are questioning its effectiveness without concurrent topical Minoxidil application.

The user experiences severe side effects from finasteride and dutasteride, including low libido and anxiety, and is currently using oral minoxidil despite shortness of breath. They are seeking alternative treatments for hair loss, having tried pyrilutamide, fluridil, and RU58841 with no success, and are considering future treatments or a hair transplant.

AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.

The conversation is about using Winlevi Clascoterone cream for hair loss. The user is considering adding it to their routine, which includes a topical hair growth serum, and is seeking feedback on its effectiveness.

The user has been using finasteride, minoxidil, and biotin for 10 months with no noticeable regrowth. Suggestions include trying dutasteride, microneedling, and other treatments, but results remain uncertain.